MedTrace Logo

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

NCT04843540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-07-20

No results posted yet for this study

Summary

This is a Phase 1 open-label study of the effect of rifampin on the pharmacokinetics of CTP-543 in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CTP-543

Rifampin as oral capsule

Sponsors & Collaborators

  • Concert Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-19
Primary Completion
2021-06-24
Completion
2021-07-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04843540 on ClinicalTrials.gov